May 11--WHO announced Democratic Republic of Congo Ebola outbreak, with one lab confirmed case of Ebola. 9 suspected cases currently. Outbreak reportedly in remote area of DRC.
Crusher 4 U
profit taking day, tomorrow it will get green again!!!
Very strange reaction to what can only described as very positive interim data increasing the ORR from pembolizumab alone at 33% to 59% in the combination arm for the non-ocular melanoma and an even more impressive 52% if the ocular melanoma patients are included; no idea why that causes the shares to drop.
NLNK had 60 patients with 59% RR while INCY had only 19 patients with 59% RR. NLNK had 200% more patient samples and for those in the biotech world, more samples matter more than fewer patients. Anyway, thanks for the cheap shares, bought at $16, $17.
Satan er Satnam is flooding the board with his 2" c uck
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%++ UPSIDE POTENTIAL.... UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered goldmine could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)